Yinhong Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yinhong Song has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Yongqin Zhou
Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy China Three Gorges University Yichang China
4 shared publicationsLihong Cui
College of Basic Medical Science, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang Key Laboratory of Infection and Inflammation China Three Gorges University Yichang Hubei China
3 shared publicationsJingyi Zhang
China Three Gorges University
2 shared publicationsLanlan Yin
China Three Gorges University
2 shared publicationsLanqi Shang
Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, People’s Republic of China
2 shared publicationsMengting Lun
Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, People’s Republic of China
2 shared publications
Latest Publications
- 4 November 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 33, 1-14
Immunomodulatory Effects of Extracts and Active Biomolecules of Morinda officinalis How: A Review
Introduction/Objective: Global population aging and the rising burden of immunosenescencerelated disorders have created an urgent need for safe, low-toxicity immunomodulators suitable for middleaged and elderly populations. Morinda officinalis How (MO, called “Ba-Ji-Tian” in China), a traditional Chinese kidney-tonifying herb, has shown promising immunomodulatory activity. This review aims to integrate current knowledge on the multidimensional immunomodulatory functions and regulatory networks of MO extracts and their major active biomolecules and summarize their mechanistic contributions in immune-related diseases. Methods: Peer-reviewed literature published over the past decade was comprehensively searched and systematically appraised to evaluate the in vitro and in vivo immunomodulatory effects of MO extracts and their major active constituents, including MO polysaccharides, oligosaccharides, iridoid glycosides, anthraquinones, and sterols. Results: Accumulating evidence indicates that MO exerts bidirectional immunoregulation by modulating cytokine secretion, promoting the proliferation and activation of immune cells including lymphocytes and macrophages, and increasing immune organ indices. Its representative compounds, such as monotropein, rubiadin, physcion, daucosterol, and stigmasterol, contribute to these effects and help alleviate aging-related chronic inflammatory diseases. Discussion: MO extracts and active biomolecules exhibit marked immunomodulatory properties. However, these findings vary across experimental models and doses, and the molecular mechanism remains incompletely defined. Standardized extracts and mechanism-oriented studies are therefore needed to support translational development. Conclusion: MO and its active biomolecules represent promising, mildly acting immunomodulators with considerable potential for clinical application in aging-related immune dysfunction.
- 4 November 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 33, 1-14
Immunomodulatory Effects of Extracts and Active Biomolecules of Morinda officinalis How: A Review
Introduction/Objective: Global population aging and the rising burden of immunosenescencerelated disorders have created an urgent need for safe, low-toxicity immunomodulators suitable for middleaged and elderly populations. Morinda officinalis How (MO, called “Ba-Ji-Tian” in China), a traditional Chinese kidney-tonifying herb, has shown promising immunomodulatory activity. This review aims to integrate current knowledge on the multidimensional immunomodulatory functions and regulatory networks of MO extracts and their major active biomolecules and summarize their mechanistic contributions in immune-related diseases. Methods: Peer-reviewed literature published over the past decade was comprehensively searched and systematically appraised to evaluate the in vitro and in vivo immunomodulatory effects of MO extracts and their major active constituents, including MO polysaccharides, oligosaccharides, iridoid glycosides, anthraquinones, and sterols. Results: Accumulating evidence indicates that MO exerts bidirectional immunoregulation by modulating cytokine secretion, promoting the proliferation and activation of immune cells including lymphocytes and macrophages, and increasing immune organ indices. Its representative compounds, such as monotropein, rubiadin, physcion, daucosterol, and stigmasterol, contribute to these effects and help alleviate aging-related chronic inflammatory diseases. Discussion: MO extracts and active biomolecules exhibit marked immunomodulatory properties. However, these findings vary across experimental models and doses, and the molecular mechanism remains incompletely defined. Standardized extracts and mechanism-oriented studies are therefore needed to support translational development. Conclusion: MO and its active biomolecules represent promising, mildly acting immunomodulators with considerable potential for clinical application in aging-related immune dysfunction.
- 24 September 2026
- Published by Wiley in Luminescence
- Vol. 41 (9) , e70627
Fabrication of Protein A–Functionalized Silica‐Encapsulated Carbon Dot Bioconjugates for Cellular Fluorescence Imaging
Fluorescent probes are widely employed in biofluorescence analysis and biomedical imaging. In this study, uniform spherical silica‐encapsulated silicon‐nitrogen co‐doped carbon dots (Si‐MPD‐CDs@SiO 2 ) with a particle size of 24 ± 15 nm were prepared via a modified Stöber method. The nanocomposites were further carboxylated and covalently conjugated with Protein A to construct Si‐MPD‐CDs@SiO 2 @PA bioconjugates. The resulting nanoprobe was successfully applied for specific immunofluorescence labeling and imaging of immortalized mouse thymic epithelial cells (iTECs). Compared with commercial fluorescent secondary antibodies, Si‐MPD‐CDs@SiO 2 @PA exhibit multiple superiorities including low cost, facile preparation and purification, favorable surface modifiability, strong fluorescence emission, and high photostability. These results indicate that Si‐MPD‐CDs@SiO 2 @PA can serve as a promising fluorescent nanoprobe for targeted cellular imaging and related biomedical applications.
- 24 September 2026
- Published by Wiley in Luminescence
- Vol. 41 (9) , e70627
Fabrication of Protein A–Functionalized Silica‐Encapsulated Carbon Dot Bioconjugates for Cellular Fluorescence Imaging
Fluorescent probes are widely employed in biofluorescence analysis and biomedical imaging. In this study, uniform spherical silica‐encapsulated silicon‐nitrogen co‐doped carbon dots (Si‐MPD‐CDs@SiO 2 ) with a particle size of 24 ± 15 nm were prepared via a modified Stöber method. The nanocomposites were further carboxylated and covalently conjugated with Protein A to construct Si‐MPD‐CDs@SiO 2 @PA bioconjugates. The resulting nanoprobe was successfully applied for specific immunofluorescence labeling and imaging of immortalized mouse thymic epithelial cells (iTECs). Compared with commercial fluorescent secondary antibodies, Si‐MPD‐CDs@SiO 2 @PA exhibit multiple superiorities including low cost, facile preparation and purification, favorable surface modifiability, strong fluorescence emission, and high photostability. These results indicate that Si‐MPD‐CDs@SiO 2 @PA can serve as a promising fluorescent nanoprobe for targeted cellular imaging and related biomedical applications.
- Open Access
- 13 July 2026
- Published by Wiley in Aging Cell
- Vol. 25 (7) , e70630
GW9508 ‐Induced Activation of GPR40 in Thymic Epithelial Cells: A Therapeutic Strategy to Delay Thymic Aging
Age‐associated thymic involution leads to a reduction of T‐cell production, which constitutes a primary factor in immunosenescence, thereby increasing vulnerability to cancer, infections, and autoimmune disorders. Thymic epithelial cells (TECs), essential for T‐cell development, exhibit progressive senescence with aging. The development of strategies to mitigate TECs senescence and delay thymic degeneration has emerged as a significant research focus. Here, aged C57BL/6J mice and immortalized thymic epithelial cells (iTECs) were hired. The marked reduction of GPR40 expression was observed in TECs from aged mice and in senescent iTECs induced by doxorubicin in vitro. Administration of the GPR40 agonist GW9508, antagonist GW1100, or their combination to aged mice or senescent iTECs demonstrated that GPR40 activation effectively restored thymic function in aged mice. Mechanistically, GW9508 targeted GPR40 to elevate intracellular calcium ion levels, thereby activating the AMPK signaling pathway and inhibiting the hyperactivation of the ERK1/2‐MAPK pathway in senescent cells, ultimately enhancing the activity of aged iTECs. Collectively, these findings suggest that the exogenous activation of GPR40 by GW9508 may represent a viable strategy to alleviate thymic senescence and enhance immune function in aged individuals.
- 13 July 2026
- Published by Wiley in Aging Cell
- Vol. 25 (7) , e70630
Open AccessGW9508 ‐Induced Activation of GPR40 in Thymic Epithelial Cells: A Therapeutic Strategy to Delay Thymic Aging
Age‐associated thymic involution leads to a reduction of T‐cell production, which constitutes a primary factor in immunosenescence, thereby increasing vulnerability to cancer, infections, and autoimmune disorders. Thymic epithelial cells (TECs), essential for T‐cell development, exhibit progressive senescence with aging. The development of strategies to mitigate TECs senescence and delay thymic degeneration has emerged as a significant research focus. Here, aged C57BL/6J mice and immortalized thymic epithelial cells (iTECs) were hired. The marked reduction of GPR40 expression was observed in TECs from aged mice and in senescent iTECs induced by doxorubicin in vitro. Administration of the GPR40 agonist GW9508, antagonist GW1100, or their combination to aged mice or senescent iTECs demonstrated that GPR40 activation effectively restored thymic function in aged mice. Mechanistically, GW9508 targeted GPR40 to elevate intracellular calcium ion levels, thereby activating the AMPK signaling pathway and inhibiting the hyperactivation of the ERK1/2‐MAPK pathway in senescent cells, ultimately enhancing the activity of aged iTECs. Collectively, these findings suggest that the exogenous activation of GPR40 by GW9508 may represent a viable strategy to alleviate thymic senescence and enhance immune function in aged individuals.
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-16
A Comprehensive Review of Hedyotis Diffusa Willd–Scutellaria Barbata D. Don Herb Pair in Anti- Hepatocellular Carcinoma Effects and Their Combinatorial Effects and Mechanisms
Hepatocellular carcinoma (HCC) is among the most prevalent malignancies of the digestive system, with a global rising incidence. Hedyotis diffusa Willd and Scutellaria barbata D. Don are classic herb pair in traditional Chinese medicine (TCM) of clearing heat and detoxifying, and is widely applied in the treatment of HCC. Although existing research has confirmed their efficacy against HCC through modulation of apoptosis, proliferation, angiogenesis, and immune responses, it is noteworthy that the combined or newly generated components after the compatibility of the two herbs exhibit even more pronounced therapeutic effects. In order to verify the pharmacological activity of the combination of Hedyotis diffusa Willd and Scutellaria barbata D. Don, it is necessary to try more in vitro and in vivo models. This review synthesizes current evidence on their TCM compatibility principles, pharmacological actions, and related signaling pathways of this herb pair, providing a rigorous theoretical foundation to guide rational clinical application and further translational research on the compatibility mechanism of the Hedyotis diffusa Willd–Scutellaria barbata D. Don herb pair in the treatment of HCC.
- 1 June 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-16
Open AccessA Comprehensive Review of Hedyotis Diffusa Willd–Scutellaria Barbata D. Don Herb Pair in Anti- Hepatocellular Carcinoma Effects and Their Combinatorial Effects and Mechanisms
Hepatocellular carcinoma (HCC) is among the most prevalent malignancies of the digestive system, with a global rising incidence. Hedyotis diffusa Willd and Scutellaria barbata D. Don are classic herb pair in traditional Chinese medicine (TCM) of clearing heat and detoxifying, and is widely applied in the treatment of HCC. Although existing research has confirmed their efficacy against HCC through modulation of apoptosis, proliferation, angiogenesis, and immune responses, it is noteworthy that the combined or newly generated components after the compatibility of the two herbs exhibit even more pronounced therapeutic effects. In order to verify the pharmacological activity of the combination of Hedyotis diffusa Willd and Scutellaria barbata D. Don, it is necessary to try more in vitro and in vivo models. This review synthesizes current evidence on their TCM compatibility principles, pharmacological actions, and related signaling pathways of this herb pair, providing a rigorous theoretical foundation to guide rational clinical application and further translational research on the compatibility mechanism of the Hedyotis diffusa Willd–Scutellaria barbata D. Don herb pair in the treatment of HCC.
- Open Access
- 23 April 2026
- Published by World Scientific Pub Co Pte Ltd in Journal of Innovative Optical Health Sciences
- Vol. 19 (06)
Decoding cellular crosstalk to inhibit angiogenesis in rheumatoid arthritis: Integrated approaches for targeted intervention and vascular imaging
Rheumatoid arthritis (RA) is a chronic autoimmune disease pathologically defined by the formation of pannus, a highly vascularized tissue with pronounced proliferative, invasive, and destructive properties. With the molecular mechanisms of angiogenesis becoming increasingly elucidated, targeted interventions are now being developed to disrupt the pro-angiogenic cellular network within the pannus, which is orchestrated by activated endothelial cells, invasive fibroblasts, and infiltrating immune cells. From the perspective of early detection, sensitive noninvasive imaging techniques, including photoacoustic, ultrasound, and nuclear imaging, enable visualization of angiogenesis in RA joints, providing a critical window for timely diagnosis and antiangiogenic treatment. This review synthesizes recent advances in RA angiogenesis research, particularly focusing on molecular mechanisms, novel targeted therapeutic strategies, and advanced imaging techniques for in vivo assessment. Collectively, these developments highlight the paradigm of image-guided antiangiogenic theranostics, which integrates real-time visualization of neovascularization with nanomaterial-based targeted therapeutic intervention to offer a refined approach for early RA management.
- 23 April 2026
- Published by World Scientific Pub Co Pte Ltd in Journal of Innovative Optical Health Sciences
- Vol. 19 (06)
Open AccessDecoding cellular crosstalk to inhibit angiogenesis in rheumatoid arthritis: Integrated approaches for targeted intervention and vascular imaging
Rheumatoid arthritis (RA) is a chronic autoimmune disease pathologically defined by the formation of pannus, a highly vascularized tissue with pronounced proliferative, invasive, and destructive properties. With the molecular mechanisms of angiogenesis becoming increasingly elucidated, targeted interventions are now being developed to disrupt the pro-angiogenic cellular network within the pannus, which is orchestrated by activated endothelial cells, invasive fibroblasts, and infiltrating immune cells. From the perspective of early detection, sensitive noninvasive imaging techniques, including photoacoustic, ultrasound, and nuclear imaging, enable visualization of angiogenesis in RA joints, providing a critical window for timely diagnosis and antiangiogenic treatment. This review synthesizes recent advances in RA angiogenesis research, particularly focusing on molecular mechanisms, novel targeted therapeutic strategies, and advanced imaging techniques for in vivo assessment. Collectively, these developments highlight the paradigm of image-guided antiangiogenic theranostics, which integrates real-time visualization of neovascularization with nanomaterial-based targeted therapeutic intervention to offer a refined approach for early RA management.
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 10821-10833
Recent Advances in Host Immune Mechanisms Against Listeria monocytogenes Infection
Listeria monocytogenes (Lm) is a foodborne Gram-positive pathogenic bacterium that primarily causes clinical manifestations such as sepsis, meningitis, and monocytosis. The main susceptible populations include newborns, pregnant women, adults over 40 years old, and immunocompromised individuals. Currently, antibiotic therapy remains the primary clinical treatment, but in recent years the issue of antibiotic resistance has become increasingly prominent. This review summarizes recent advances in host immune mechanisms against Lm infection, focusing on: (1) the defensive roles of host barrier systems (intestinal, blood-brain, and placental barriers); (2) innate immune responses, including pathogen recognition via TLRs/NLRs signaling pathways, macrophage phagocytosis, and NK cell immune surveillance; and (3) adaptive immunity, particularly CD4+/CD8+ T cell-mediated specific immune responses and the long-term protective effects of memory T cells. By systematically elucidating the molecular mechanisms of these immune processes, this review aims to provide novel therapeutic strategies through enhancement of host immune functions for clinical management of Lm infection.
- 1 August 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 10821-10833
Open AccessRecent Advances in Host Immune Mechanisms Against Listeria monocytogenes Infection
Listeria monocytogenes (Lm) is a foodborne Gram-positive pathogenic bacterium that primarily causes clinical manifestations such as sepsis, meningitis, and monocytosis. The main susceptible populations include newborns, pregnant women, adults over 40 years old, and immunocompromised individuals. Currently, antibiotic therapy remains the primary clinical treatment, but in recent years the issue of antibiotic resistance has become increasingly prominent. This review summarizes recent advances in host immune mechanisms against Lm infection, focusing on: (1) the defensive roles of host barrier systems (intestinal, blood-brain, and placental barriers); (2) innate immune responses, including pathogen recognition via TLRs/NLRs signaling pathways, macrophage phagocytosis, and NK cell immune surveillance; and (3) adaptive immunity, particularly CD4+/CD8+ T cell-mediated specific immune responses and the long-term protective effects of memory T cells. By systematically elucidating the molecular mechanisms of these immune processes, this review aims to provide novel therapeutic strategies through enhancement of host immune functions for clinical management of Lm infection.
- Open Access
- 8 May 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 157, 114791
Transcription factors FOXN1 and intrathymic cytokines contribute to dysfunction of TECs during lipopolysaccharide-induced thymic atrophy
- 8 May 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 157, 114791
Open AccessTranscription factors FOXN1 and intrathymic cytokines contribute to dysfunction of TECs during lipopolysaccharide-induced thymic atrophy
- 23 April 2025
- Published by Elsevier in Fitoterapia
- Vol. 183, 106567
4, 9-dihydroxy-α-lapachone as a potent antiproliferation agent for triple-negative breast cancer via ferroptosis
- 23 April 2025
- Published by Elsevier in Fitoterapia
- Vol. 183, 106567
4, 9-dihydroxy-α-lapachone as a potent antiproliferation agent for triple-negative breast cancer via ferroptosis
- Open Access
- 23 April 2024
- Published by Springer Nature in Research Square
Acanthopanax senticosus polysaccharides attenuates Klebsiella infection in immunocompromised mice by modulating immunity
Radiotherapy and chemotherapy compromise individuals’ immunity clinically, resulting in increased opportunistic infections. In this study, the cyclophosphamide-induced immunocompromised C57BL/6J mouse with Klebsiella infection was hired to analyze the effect of the active components of Acanthopanax senticosus on anti-infection for immunocompromised individuals. As a result, Acanthopanax senticosus polysaccharide (ASPS) was selected with the best effect. For immunocompromised C57BL/6J mouse, ASPS increased its indices of thymus and spleen, reducing the bacteria load in lung and protecting the function of liver. Meanwhile, ASPS obviously boosted the total number of thymocytes and the number of CD4+ T cells in spleen, promoting the proportions of CD4+ TCM and TEM cells, while decreasing that of CD4+ TEMRA cells in in peripheral blood. Moreover, ASPS enhanced the number of NF-κB+, CD192+ Mφ and NF-κB+ neutrophils in the abdomen and strengthened their antibacterial function, however, reduced the number of NF-κB+ Mφ and neutrophils in the spleen reducing inflammation. It is also observed by immunofluorescence that the NF-κB expression of peritoneal Mφ increased evidently after the mice were treated with ASPS. In conclusion, ASPS has an obvious effect against infection for immunocompromised mice by promoting immunity recovery.
- 23 April 2024
- Published by Springer Nature in Research Square
Open AccessAcanthopanax senticosus polysaccharides attenuates Klebsiella infection in immunocompromised mice by modulating immunity
Radiotherapy and chemotherapy compromise individuals’ immunity clinically, resulting in increased opportunistic infections. In this study, the cyclophosphamide-induced immunocompromised C57BL/6J mouse with Klebsiella infection was hired to analyze the effect of the active components of Acanthopanax senticosus on anti-infection for immunocompromised individuals. As a result, Acanthopanax senticosus polysaccharide (ASPS) was selected with the best effect. For immunocompromised C57BL/6J mouse, ASPS increased its indices of thymus and spleen, reducing the bacteria load in lung and protecting the function of liver. Meanwhile, ASPS obviously boosted the total number of thymocytes and the number of CD4+ T cells in spleen, promoting the proportions of CD4+ TCM and TEM cells, while decreasing that of CD4+ TEMRA cells in in peripheral blood. Moreover, ASPS enhanced the number of NF-κB+, CD192+ Mφ and NF-κB+ neutrophils in the abdomen and strengthened their antibacterial function, however, reduced the number of NF-κB+ Mφ and neutrophils in the spleen reducing inflammation. It is also observed by immunofluorescence that the NF-κB expression of peritoneal Mφ increased evidently after the mice were treated with ASPS. In conclusion, ASPS has an obvious effect against infection for immunocompromised mice by promoting immunity recovery.
- Open Access
- 7 July 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1214675
Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential
Lysine-specific demethylase 1 (LSD1) is an enzyme that removes lysine methylation marks from nucleosome histone tails and plays an important role in cancer initiation, progression, metastasis, and recurrence. Recent research shows that LSD1 regulates tumor cells and immune cells through multiple upstream and downstream pathways, enabling tumor cells to adapt to the tumor microenvironment (TME). As a potential anti-tumor treatment strategy, immunotherapy has developed rapidly in the past few years. However, most patients have a low response rate to available immune checkpoint inhibitors (ICIs), including anti-PD-(L)1 therapy and CAR-T cell therapy, due to a broad array of immunosuppressive mechanisms. Notably, inhibition of LSD1 turns “cold tumors” into “hot tumors” and subsequently enhances tumor cell sensitivity to ICIs. This review focuses on recent advances in LSD1 and tumor immunity and discusses a potential therapeutic strategy for combining LSD1 inhibition with immunotherapy.
- 7 July 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1214675
Open AccessTargeting LSD1 in tumor immunotherapy: rationale, challenges and potential
Lysine-specific demethylase 1 (LSD1) is an enzyme that removes lysine methylation marks from nucleosome histone tails and plays an important role in cancer initiation, progression, metastasis, and recurrence. Recent research shows that LSD1 regulates tumor cells and immune cells through multiple upstream and downstream pathways, enabling tumor cells to adapt to the tumor microenvironment (TME). As a potential anti-tumor treatment strategy, immunotherapy has developed rapidly in the past few years. However, most patients have a low response rate to available immune checkpoint inhibitors (ICIs), including anti-PD-(L)1 therapy and CAR-T cell therapy, due to a broad array of immunosuppressive mechanisms. Notably, inhibition of LSD1 turns “cold tumors” into “hot tumors” and subsequently enhances tumor cell sensitivity to ICIs. This review focuses on recent advances in LSD1 and tumor immunity and discusses a potential therapeutic strategy for combining LSD1 inhibition with immunotherapy.